Elite Pharmaceuticals Inc (QB) (ELTP) Share Price

Gotta laugh...almost out loud

Love your style. You were in GMDA as well on stocktwits? Could be wrong. Just asking. If yes Abby should be locked up.

Why do you say this? Isn't IQ IA for Xarelto about 10B? Didn't think it was large enough in magnitude to near $27B figure provided. 

Based upon key patent expiration dates, it would appear that Elite's bioequivalent study was for Xarelto and not Eliquis. Perhaps this will cause the manufacturers, Bayer and/or J&J to consider making a bid to eliminate possible competition. At the very least, it should raise awareness of a new sheriff in town.

Hammered Time

I'm not quite sure how to react to whoever responded with a curling stone emoji. 😂 I can't believe there is even an emoji for that, let alone what it symbolizes.

I'm really impressed with your civil engineering prowess to whip out all these bridges so fast.

$7? Before that imaginary, never coming, always gets pushed out buyout comes, can I sell you a bridge? You definitely sound like a good prospect.

The shortMfers will drag it down to 30-40 cents before the news comes out. Same pattern for years.
Stop the steal and don’t have idle shares sitting around. I have over half a million to sell at $7. In no hurry.

IB, DOLLARLAND is not years away. DOLLARLAND is weeks away or definitely in August 2025 with the reports of record breaking revenues from all of Elite's drugs but mainly the generic versions of Adderall IR, Adderall XR, Percocet, Norco, and Vyvanse!!!

Wonderful, coincides with that 2028 buyout rumors. Those will be starting now. New narrative. Old one is done, and need more exit liquidity. Kool aide is turning sour. Don't drink it.

Branded Anticoagulants patent expiration dates are all over the calendar with formulation patent expiration dates and dosage patent expiration dates. Keep in mind for all anticoagulants with patents that have not expired, FDA will not approve their ANDA for a generic version until the patent expires. FDA will send a letter say FDA finds the drug bioequivalent however cannot approve ANDA until patent expires. So, in consideration of Elite's bioequivalence Study PR to the future launch of Elites anticoagulant generic drug product timeline, it is hard to determine which drug they are targeting.

Rivaroxaban (Xarelto; Bayer)
Rivaroxaban (Xarelto; Bayer), a direct oral anticoagulant (DOAC) widely prescribed for preventing stroke, venous thromboembolism, and recurrent cardiovascular events, is approaching its final patent expiration in 2025. The solid oral formulation patent, including pediatric exclusivity, is scheduled to expire in May 2025. In anticipation, the FDA approved the first generic versions of rivaroxaban 2.5-mg tablets in March 2025, indicated for reducing major cardiovascular and thrombotic events in patients with coronary artery disease and peripheral artery disease.
In contrast, apixaban (Eliquis; Bristol Myers Squibb and Pfizer), another leading DOAC, has a more complex patent landscape. Although certain patents are set to expire in 2026, court rulings have delayed generic competition in the US until at least 2028. Bristol Myers Squibb expects generic entry for Eliquis to begin on April 1, 2028.

Xarelto - Bayer / J&J - Key patent expiration: 2026
Patented in 2007 and approved for medical use in the United States in 2011, Xarelto (Rivaroxaban) is used to treat and prevent blood clots. The anticoagulant, which was jointly developed by Bayer and J&J's Janssen Pharmaceuticals (now Innovative Medicines), has been prescribed more than 80 million times in the US alone. In 2022, it was Bayer’s bestselling pharmaceutical product, bringing in €4,516 million worth of revenue.
Over the years, Bayer has had to protect its patent at a national level in a number of countries and there have already been patent law disputes that have been resolved through settlements. Bayer anticipates it may need to further defend its patent over the coming years but it is expected to lose exclusivity for Xarelto in 2026.

Eliquis - Bristol Myers Squibb & Pfizer - Key patent expirations: 2027 to 2029
Eliquis (Apixaban) is a medicine used to prevent blood clots in adults. Approved for medical use in the European Union in May 2011, and in the United States in December 2012, Eliquis has become one of the most effective treatment options for DVT and PE.
With Eliquis' patent due to come to an end in the next few years, generic versions of Bristol Myers Squibb and Pfizer’s Eliquis have already secured provisional FDA nods. However, thanks to settlements and a key lawsuit, the pair have been able to fend off those cheaper rivals until at least 2027.
For now, it's unclear when Eliquis generics might start to come in, but it is believed generics wouldn’t come into play until 2027 because of the possibility of a paediatric extension under FDA rules, which would add six months of market exclusivity.

SAVAYSA is protected by two U.S. patents and one FDA regulatory exclusivity, with the earliest potential generic entry date estimated to be March 28, 2028.

Hi weezhul you may want to add to your list the billions of shares THAT WERE NOT ADDED to the elite share count because Mikah stepped in and prevented a dilution that would have impacted each and all of us when the share price was 3 cents.

We can launch in other countries and overseas beginning at the end of next year - 2026.

And then we launch in the U.S. in 2028.

Also, the worldwide market is the EXACT same size as the U.S. market.

Thanks.

Did you “Top Off” Today? Lmao

Using the Inflation Reduction Act to Rein in Patenting & Evergreening Abuses
December 11, 2024

https://www.citizen.org/article/using-the-inflation-reduction-act-to-rein-in-patenting-evergreening-abuses/
Eliquis (Apixaban)
Apixaban (marketed as Eliquis) is a blood thinner used to treat blood clots which received FDA approval in 2012, and is marketed through a collaboration between Bristol Myers Squibb (BMS) and Pfizer.[90] From June 2022 to May 2023, Medicare Part D spent a colossal $16,482,621,000 to cover the cost of Eliquis for more than 3.7 million enrollees.[91] The drug, on average, costs the program $4,448 per enrollee, with an annual out-of-pocket cost amounting to more than $600 for just this one drug among enrollees who did not receive low-income subsidies.[92] In 2023, BMS and Pfizer made a staggering $12.2 billion and $6.7 billion off the drug, respectively.[93] Although the FDA approved generics for the drug in 2019,[94] none will come to market in the United States until April 1, 2028 because BMS and Pfizer had sued 25 generic manufacturers to delay generic competition on their lucrative drug.[95] By contrast, generics are already available in Canada and the United Kingdom.[96] To delay generic entry, BMS and Pfizer rely on a secondary patent covering a crystalline version of the active ingredient to unfairly extend monopoly control on the drug.

Prolonging Monopoly Protections with Crystalline Patents
According to the Orange Book, BMS’s patent covering the drug substance for apixaban was filed in September 2002, and was set to expire in February 2023.[97] But BMS received an extension of its patent term until November 2026 from the U.S. Patent & Trademark Office using a federal law that can extend a patent term for time lost in the premarket government approval process.[98] BMS and Pfizer also own a patent on a crystalline version of apixaban that dissolves faster in the body, which increases its bioavailability (the amount of the drug that gets into the blood).[99] This patent extended exclusivity over the drug until 2031 and allowed the companies to extract settlement agreements delaying generic entry until 2028.[100]

As experts have written, crystalline patents are obvious variations of the original compound of a drug, the patenting of which allows drug companies to prolong their monopoly protections and block generic competitors.[101] This is because these variations can differ in important therapeutic properties, like drug product performance, bioavailability, and stability, so the FDA released guidance in 2000 recommending routine testing to monitor and control these forms as part of the approval process of drugs.[102] From the perspective of seeking to promote new and useful inventions, there is little value to awarding additional monopoly protections for a standard screening procedure employed widely by industry to monitor forms that already exist inherently in the original compound. These forms would be discovered in any case during the drug approval process.

In sum, BMS and Pfizer have leveraged this crystalline patent against manufacturers in settlements to unfairly delay generic entry until April 2028, when patent protection in the drug should have expired by November 2026. Medicare enrollees, as well as the public at large, will pay the hefty price for this evergreening practice given that the drug costs the program over $16 billion a year.

Going up from now on. It was a long post. Lol

So it's only 4 years away at the earliest ............................

I'm excited to be watching the years go by waiting on This Monster "ELTP" to get to "Dollarland" !!!!!!!!!!!!!!!!!!!!!!!!!!!!

Exciting Times,

IB_🤴

No U.S. Eliquis launch until 2031 or 2040:

- "Eliquis, co-owned by Bristol Myers Squibb and Pfizer, has five additional patents granted, with the last one expiring in November 2040. These patents, which cover minor modifications to the drug, provide extended protection beyond the initial patent for the original compound. One of these patents, U.S. Patent No. 9,326,945, is being used to delay generic competition and is set to expire in February 2031."

HOWEVER, we may be able to launch in Europe NEXT YEAR - 2026:

- "While Eliquis patents continue to be challenged in certain EU countries, patent expiry in key EU markets is expected to occur in the second half of 2026."

The Bristol Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis® Patents
PRINCETON, N.J. & NEW YORK, N.Y.

September 3, 2021 – The Bristol Myers Squibb-Pfizer Alliance today issued the following statement:

We welcome the decision by the Court of Appeals for the Federal Circuit’s to affirm the U.S. District Court’s August 2020 decision finding the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9,326,945) covering Eliquis® valid and infringed. Given today’s decision, the earliest that generic manufacturers are permitted to launch their apixaban products is April 1, 2028, subject to additional appeals and challenges.

https://news.bms.com/news/corporate-financial/2021/The-Bristol-Myers-Squibb-Pfizer-Alliance-is-pleased-with-the-decision-by-the-U.S.-Court-of-Appeals-for-the-Federal-Circuit-upholding-the-Eliquis-Patents/default.aspx


According to FDA Orange Book, there are currently 13 approved ANDA's for apixaban 2.5mg and 5mg tablets, none of them able to enter the market until at least 2028. Also according to Orange Book, Bristol Myers enjoys NPP exclusivity through 4/17/28 and pediatric exclusivity through 10/17/28. It is possible at least one of the ANDA's may have first to file exclusivity for 6 months after that. Looks like the earliest entry for Elite Pharma's version of apixaban is mid 2029.

.

Global

Thought someone named alma was the originator

As a reminder, the Revenue Guessing Game, which I invented, begins THIS Monday, June 23.

Thanks.

NEXT WEEK:

✅️ Methadone launch

and/or

✅️ Adderall Israel launch

$27 billion US or global market?

Nasrat: "Elite is the leader in the industry in the IR and ER, and we will be as well in Lisdex."

Orange Book

https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

Search : XARELTO

Doesn't matter if we're first to file.

We capture the #1 🥇 market share REGARDLESS of when we enter:

Adderall IR: 🥇
Adderall XR: 🥇
Vyvanse: (#1 🥇 soon)

So then that rules out us being first to file if true, right?

Still a huge opportunity for Elite either way though.

If it's really that good I sure hope the brand owner doesnt somehow get an extension on their patent

You know how corrupt BP is

Fingers crossed

I was wondering what a $27 Billion ANDA will do for us.
How many multiples has this news raised the Buyout price.
Thoughts ?

Only so many days left to top off.
https://www.timeanddate.com/countdown/payday?iso=20250630T1615&p0=179&msg=HammerTime+%21%21&font=cursive

Doesn't need pumpers. It's getting bought out. No wait, its getting uplisted. No wait, its going to merge. No wait, a RS is coming. No wait, the timelines and narratives change need more time for the exit liquidity. Here's all you need to know. Kool aide is bitter. Bridges are bright.
https://www.reddit.com/r/wallstreetbets/comments/1l7a5hj/my_1_million_investment_triple_up_is_about_to/

Always been cautiously optimistic or I wouldn't invest, but Vyvanse launch and especially with anticoagulant progress brings it to a whole new level.  Been wanting to move away from CNS for while now. Very happy to see it finally coming to fruition.

Welcome to the club of the enthusiasts

Moving away from DEA with a huge drug is a new beginning for us. We've always had to fight with quota and that has been one of our limiting factors. Let's see what else is in the pipe. 😃

This turd needs fresh pumpers! The current crew is run their course.

Pas vrai, peut etre je suis trop enthusiaste. 😂

NO, A BUYOUT!!!!!!

You mean a more successful uplisting.

Elite's buyout price exponentially went up.

One of Elite's previous ANDA's was filed in LESS than 60 days after a successful BE press release.

Elite's $27 billion anticoagulant generic drug product timeline should follow similar to their timeline for Generic Vyvanse. Could move faster as Elite has become very successful in this process and being the first to file may open some doors to move faster!

No, ELITE will be concerned with the patent expiration, JUST like we're doing right now with Generic OxyContin.

The big buyer of Elite will be concerned with timing of patent expiration.

And will get us to buy the Adderall ownership from Mikah by the mid-August CC (if it hasn't happened already).

Vyvanse will get us out of debt

He is from Mustafar. They don't need blood thinners on that planet.

Tu pompes aujourd’hui!!!😜

Sharkey. Based on how you write you must be a doctor or a good AI prompt engineer. Have a great Juneteenth.

What planet are you from? It says 27 billion in the PR hasn't been corrected. It's been verified 27 billion. Good try

Vyvanse will get us out of debt, allow greater investment and grow the financials in such a way that Elite can really scale operations and be financially ready to take on significant amounts of raw material to be processed for a much larger drug. Would love to see this come to fruition. Love that Eloquis is out of the hands of the DEA and quota won't be an issue. We're finally diversifying way from CNS portfolio. The other little products we have don't provide much diversification, especially with how large Vyvanse can be.

Not concerned why because it's not if .......it's when!  that's money in the bank they are always looking for a future revenues. That's huge one year two years means nothing for this type of market. It's huge. What are they gonna make 2 to 5 years from now? huge Choo Choo huge $$$$

Looking forward to seeing either a global partnership or acquisition by a big global player.